FDA Calendar


Company Name Astellas Pharma Inc.
Drug Name Mirabegron (NDA)
Event Name FDA decision on Mirabegron for proposed treatment of overactive bladder
Event Date 06/29/2012
Outcome FDA approved Myrbetriq (mirabegron) for treatment of overactive bladder on June 28
Drug Status
Rival Drugs
Market Potential
Other Approvals
News
FDA Panel Backs Astellas Pharma's Overactive Bladder Drug
FDA Approves Astellas Pharma's Overactive Bladder Drug
Return to FDA Calendar